Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.74 Billion KRW | 0.72% |
| 2022 | 7.26 Billion KRW | 11.83% |
| 2021 | 6.49 Billion KRW | 19.07% |
| 2020 | 5.45 Billion KRW | 19.42% |
| 2019 | 4.56 Billion KRW | 10.61% |
| 2018 | 4.13 Billion KRW | 23.39% |
| 2017 | 3.34 Billion KRW | -1.02% |
| 2016 | 3.38 Billion KRW | 36.76% |
| 2015 | 2.47 Billion KRW | -5.75% |
| 2014 | 2.62 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.5 Billion KRW | 4.45% |
| 2024 Q1 | 1.47 Billion KRW | -0.1% |
| 2023 Q4 | 1.47 Billion KRW | -29.13% |
| 2023 Q3 | 2.08 Billion KRW | -18.31% |
| 2023 Q2 | 2.55 Billion KRW | 65.4% |
| 2023 FY | 7.31 Billion KRW | 0.72% |
| 2023 Q1 | 1.54 Billion KRW | -21.23% |
| 2022 Q2 | 1.82 Billion KRW | 5.2% |
| 2022 Q1 | 1.73 Billion KRW | -2.92% |
| 2022 Q4 | 1.96 Billion KRW | 12.36% |
| 2022 Q3 | 1.74 Billion KRW | -4.35% |
| 2022 FY | 7.26 Billion KRW | 11.83% |
| 2021 Q3 | 1.65 Billion KRW | 7.84% |
| 2021 Q2 | 1.53 Billion KRW | 0.53% |
| 2021 Q4 | 1.78 Billion KRW | 8.08% |
| 2021 FY | 6.49 Billion KRW | 19.07% |
| 2021 Q1 | 1.52 Billion KRW | 0.3% |
| 2020 Q4 | 1.51 Billion KRW | 44.15% |
| 2020 Q3 | 1.05 Billion KRW | -33.62% |
| 2020 Q2 | 1.58 Billion KRW | 22.84% |
| 2020 Q1 | 1.29 Billion KRW | -19.2% |
| 2020 FY | 5.45 Billion KRW | 19.42% |
| 2019 FY | 4.56 Billion KRW | 10.61% |
| 2019 Q4 | 1.6 Billion KRW | 73.34% |
| 2019 Q3 | 923.2 Million KRW | -16.96% |
| 2019 Q2 | 1.11 Billion KRW | 19.12% |
| 2019 Q1 | 933.33 Million KRW | -45.11% |
| 2018 Q3 | 770.26 Million KRW | -4.41% |
| 2018 Q4 | 1.7 Billion KRW | 120.74% |
| 2018 Q1 | 853.8 Million KRW | 15.54% |
| 2018 Q2 | 805.82 Million KRW | -5.62% |
| 2018 FY | 4.13 Billion KRW | 23.39% |
| 2017 Q1 | 876.37 Million KRW | -15.56% |
| 2017 Q3 | 463.93 Million KRW | -52.46% |
| 2017 Q2 | 975.97 Million KRW | 11.36% |
| 2017 Q4 | 738.97 Million KRW | 59.29% |
| 2017 FY | 3.34 Billion KRW | -1.02% |
| 2016 Q3 | 798.79 Million KRW | -6.48% |
| 2016 Q4 | 1.03 Billion KRW | 29.92% |
| 2016 Q2 | 854.12 Million KRW | 23.61% |
| 2016 Q1 | 690.96 Million KRW | 38.82% |
| 2016 FY | 3.38 Billion KRW | 36.76% |
| 2015 Q2 | 815.66 Million KRW | 29.1% |
| 2015 FY | 2.47 Billion KRW | -5.75% |
| 2015 Q3 | 527.49 Million KRW | -35.33% |
| 2015 Q4 | 497.74 Million KRW | -5.64% |
| 2015 Q1 | 631.8 Million KRW | 0.0% |
| 2014 FY | 2.62 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 92.963% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | 1.346% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 86.098% |
| Bioneer Corporation | 204.55 Billion KRW | 96.216% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 88.149% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 76.088% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 79.286% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 97.293% |
| Medy-Tox Inc. | 110.88 Billion KRW | 93.02% |
| Peptron, Inc. | 16.65 Billion KRW | 53.531% |
| Amicogen, Inc. | 52.82 Billion KRW | 85.347% |
| Genexine, Inc. | 41.62 Billion KRW | 81.406% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | 52.122% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 92.151% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 81.092% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 91.346% |
| SillaJen, Inc. | 5.11 Billion KRW | -51.405% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | 69.841% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 78.042% |
| Genomictree Inc. | 16.26 Billion KRW | 52.412% |
| MedPacto, Inc. | 26.91 Billion KRW | 71.247% |
| D&D Pharmatech | 32.16 Billion KRW | 75.935% |
| EASY BIO,Inc. | 29.67 Billion KRW | 73.914% |
| GI Innovation, Inc. | 57.59 Billion KRW | 86.561% |